Grand Pharmaceutical Group Ltd
HKEX:512
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
3.28
5.62
|
Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Grand Pharmaceutical Group Ltd
Other Long-Term Assets
Grand Pharmaceutical Group Ltd
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
G
|
Grand Pharmaceutical Group Ltd
HKEX:512
|
Other Long-Term Assets
HK$892m
|
CAGR 3-Years
38%
|
CAGR 5-Years
51%
|
CAGR 10-Years
11%
|
|
S
|
SSY Group Ltd
HKEX:2005
|
Other Long-Term Assets
HK$216.2m
|
CAGR 3-Years
33%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-6%
|
|
U
|
United Laboratories International Holdings Ltd
HKEX:3933
|
Other Long-Term Assets
ÂĄ87.8m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-13%
|
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
Other Long-Term Assets
ÂĄ989.3m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
6%
|
||
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
Other Long-Term Assets
HK$6.1B
|
CAGR 3-Years
18%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
H
|
HUTCHMED (China) Ltd
HKEX:13
|
Other Long-Term Assets
$37.3m
|
CAGR 3-Years
15%
|
CAGR 5-Years
21%
|
CAGR 10-Years
62%
|
Grand Pharmaceutical Group Ltd
Glance View
Grand Pharmaceutical Group Ltd. engages in the development, manufacture and distribution of pharmaceutical products. The firm is principally engaged in manufacturing and sales of pharmaceutical preparations and medical devices, bio-technology products, nutrition products, specialized pharmaceutical raw materials and other products. The main products of the Company cover the anti-tumor, cardiovascular emergency pharmaceutical products and advanced cerebro-cardiovascular intervention advanced medical devices, anti-virus and anti-infection, respiratory and ear-nose-throat (ENT), bio-health products and specialized pharmaceutical ingredients.
See Also
What is Grand Pharmaceutical Group Ltd's Other Long-Term Assets?
Other Long-Term Assets
892m
HKD
Based on the financial report for Jun 30, 2024, Grand Pharmaceutical Group Ltd's Other Long-Term Assets amounts to 892m HKD.
What is Grand Pharmaceutical Group Ltd's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
11%
Over the last year, the Other Long-Term Assets growth was 8%. The average annual Other Long-Term Assets growth rates for Grand Pharmaceutical Group Ltd have been 38% over the past three years , 51% over the past five years , and 11% over the past ten years .